You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab …

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - other biologic treatment
SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Weinblatt M, McInnes I, Kremer J, et al
SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis
Annals of the Rheumatic Diseases 2016;75:717-718.